신약 연구 및 개발 바이오 기업, 회사 소개, 투자 정보 등 제공.
Location: South Korea, Gyeonggi, Seongnam-si
Employees: 11-50
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | SV Investm... | svinvest.c... |
| - | Uno Invest... | unoi.co.kr |
| - | UTC Invest... | utc.co.kr |
| - | Company K ... | kpartners.... |
| - | KTB Networ... | ktbnetwork... |
Mentions in press and media 21
| Date | Title | Description |
| 22.08.2024 | Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program | Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program Aims to strengt... |
| 30.07.2024 | Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis | SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollmen... |
| 29.03.2024 | Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Bl... | SEONGNAM, South Korea and ATLANTA, March 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collabora... |
| 27.03.2024 | Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology | SEONGNAM, South Korea and AURORA, Colo., March 27, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research col... |
| 31.10.2023 | Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC | SEONGNAM, South Korea and NEWTON, Mass., Oct. 31, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the compan... |
| 26.10.2023 | Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis | The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with the investigational product No safety concerns were rai... |
| 12.07.2023 | Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium | Bridge to join as an industry member to advance the science of early detection and speed development of novel treatments SEONGNAM, South Korea and CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Ko... |
| 30.05.2023 | Bridge Biotherapeutics to Present at the 2023 BIO International Convention | SEONGNAM, South Korea and CAMBRIDGE, Mass., May 30, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is... |
| 24.04.2023 | Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI | The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor efficacy and the intracranial activity of BBT-207 SEONGNAM, South Korea and CAMBRIDGE, Mass., April 24... |
| 19.04.2023 | Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting | New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT... |
Show more